The US Food and Drug Administration (FDA) has granted 510(k) clearance to patient monitoring solutions firm Bardy Diagnostics’ 14-day variant of the Carnation Ambulatory Monitor (CAM) patch.

The CAM patch is a P-wave centric device that acts as an ambulatory cardiac patch monitor. Another use is for arrhythmia detection.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The patch is worn on the centre of the chest, directly over the heart, to ensure optimal capture of ECG signals.

The device is available in two-day and seven-day versions. The latest 14-day variant provides extended cardiac monitoring and potentially detect less-frequent arrhythmia.

Bardy Diagnostics founder and CEO Gust Bardy said: “Comfortable dermal ECG recordings that focus on the P-wave for up to 14 days carry the potential to minimise use of costly additional rhythm diagnostic tools.

“We are excited to receive clearance from the FDA to enable clinicians the option to monitor longer and anticipate incremental detection of accurate, medically actionable data to improve patient management.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The CAM patch uses a technology that detects and records the P-wave, a small amplitude ECG signal from the atrium, providing an accurate diagnosis of arrhythmia and patient management.

Users can mail the device or take it to a physician’s office for analysis. Once the study has concluded, data transfer from the patch can occur within minutes.

In a comparator study, the CAM patch was found to detect 40% more arrhythmia, allowing more informed clinical decisions in 41% of patients when compared to the iRhythm Zio XT patch.

A separate study demonstrated significantly higher identifications of arrhythmia with Bardy’s device versus a standard Holter monitor. The cardiac patch was also able to detect arrhythmia that the Holter monitor missed or did not identify correctly.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact